10-Q: Vivani Medical Reports Q1 2025 Financial Results and Clinical Trial Progress

Vivani Medical announces Q1 2025 financial results, highlighting ongoing clinical trial progress and strategic shifts in focus.

Summary

• Vivani Medical, a clinical-stage biopharmaceutical company, released its financial results for the quarter ended March 31, 2025.
• The company is focused on developing miniaturized, subdermal drug implants using its NanoPortal technology for chronic diseases.
• Vivani's lead program, NPM-115, is in clinical-stage testing for chronic weight management.
• A strategic shift involves discontinuing efforts for a Cortigent IPO and focusing on a spin-off.
• The company successfully administered its first GLP-1 implant in the LIBERATE-1 clinical trial and achieved full enrollment in the study.
• Vivani estimates that current cash reserves will be sufficient to fund planned obligations for at least the next twelve months.
• The company reported a net loss of $6.302 million, or $0.11 per share, for the three months ended March 31, 2025, compared to a net loss of $6.039 million, or $0.12 per share, for the same period in 2024.
• Research and development expenses were $4.217 million, net of grants, compared to $3.726 million for the same period in 2024.
• General and administrative expenses were $2.340 million, net of grants, compared to $2.501 million for the same period in 2024.
• As of March 31, 2025, cash and cash equivalents totaled $13.008 million, compared to $18.352 million as of December 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and strategic initiatives, it is still operating at a loss and needs to raise additional capital. The successful administration of the first GLP-1 implant and full enrollment in the LIBERATE-1 study are positive signs, but the financial results are mixed.

Positives

• Vivani Medical is making progress with its lead program, NPM-115, for chronic weight management.
• The company is streamlining its operations by spinning off Cortigent.
• The LIBERATE-1 clinical trial is fully enrolled, indicating potential interest in the GLP-1 implant.
• Preclinical data shows promising liver fat reduction with the company's GLP-1 implant.
• Vivani believes it has sufficient cash to fund operations for at least the next twelve months.

Negatives

• Vivani Medical reported a net loss of $6.302 million for the quarter ended March 31, 2025.
• Cash and cash equivalents decreased to $13.008 million as of March 31, 2025.
• The company has a history of recurring operating losses and negative operating cash flows.

Risks

• Vivani Medical needs to raise additional capital to continue operations.
• The company is subject to risks associated with developing novel medical devices, including limitations on operating capital resources.
• Clinical trials are expensive and uncertain, and may not lead to successful product development.
• Global economic and political developments, including inflation and geopolitical disruptions, could adversely affect the company's business.
• The company is involved in ongoing litigation, which could have an adverse impact.

Future Outlook

Vivani Medical estimates that currently available cash will provide sufficient funds to enable the Company to meet its planned obligations for at least the next twelve months, with study results from LIBERATE-1 anticipated in mid-2025.

Management Comments

• Vivanis management team remains committed to identifying and exploring strategic options that will enable further development of its pioneering neurostimulation systems from legacy company Second Sight aimed at helping patients recover critical body functions.

Industry Context

Vivani Medical is operating in the competitive biopharmaceutical industry, focusing on long-acting drug delivery systems to address medication adherence, a significant challenge in chronic disease management. The company's focus on GLP-1 receptor agonists aligns with current trends in obesity and diabetes treatment.

Comparison to Industry Standards

• The document mentions that the exenatide implant generated weight loss comparable to semaglutide injections in a preclinical study, which are the active ingredients in Ozempic/Wegovy.
• The liver fat data from Vivani's GLP-1 implant is consistent with published results from similar investigations with semaglutide, the active pharmaceutical ingredient in Ozempic and Wegovy.

Legal Proceedings

• One opposition filed by Pixium Vision SA (Pixium) was pending in the European Patent Office challenging the validity of a European patent owned by Cortigent.
• We decided to allow the patent to be abandoned by the EPO, which occurred in February 2025.
• As a result, this opposition is no longer pending.
• Pixium filed suit in the Paris Commercial Court, and currently claim damages of approximately 5.1 million or about $5.6 million.
• Proceedings before the Paris Court of Appeal are pending.
• The pre-trial judge issued his order, striking out Vivani's appeal for failure to enforce the decision.
• Within two years, Vivani will have to request that the case be reinstated on the court's docket, providing evidence that the judgment has been fully enforced or, at the very least, that an agreement has been reached.
• Failing this, the appeal proceedings will lapse.

Related Party Transactions

• On November 8, 2024, the Company entered into a private sale transaction with one of its directors whereby the Company sold an aggregate of 3,968,253 shares of the Companys common stock to the director at a price of $1.26 per share.
• On March 26, 2025, the Company entered into a private sale transaction with an entity affiliated with one of its directors whereby the Company shall sell an aggregate of 7,366,071 shares of the Companys common stock to the entity, in one or more closings as provided in the purchase agreement, at a price of $1.12 per share.
• On May 12, 2025, the Company entered into a private sale transaction with an entity affiliated with one of its directors whereby the Company shall sell an aggregate of 2,912,621 shares of the Companys common stock to the entity, in two closings as provided in the purchase agreement, at a price of $1.03 per share.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The spin-off of Cortigent and ongoing operations will affect employees.
• Customers: The development of new drug implants could provide new treatment options for patients with chronic diseases.
• Partners: Collaborations with pharmaceutical companies and Okava will be important for the company's success.

Next Steps

• The company will continue to develop its lead program, NPM-115, and other drug implant candidates.
• Vivani will focus on the spin-off of Cortigent into a fully independent, publicly traded company.
• The company anticipates reporting top-line results from the LIBERATE-1 study in mid-2025.

Key Dates

Keywords

Vivani Medical, NPM-115, GLP-1 implant, Clinical trial, Weight management, Cortigent, Spin-off, Financial results, NanoPortal technology, Biopharmaceutical